Table 3.

Correlations between postoperative biochemical cure, preoperative levels of calcitonin, metastatic lymph nodes in the lateral neck, tumor diameter, and extrathyroidal extension in 56 (97%) of 58 patients with M0¹

Variables Dependant and Independent		Patients, n	OR (95% CI)	p value
Biochemical cure2 Preoperative calcitonin level	yes vs. no ≤500 vs. >500 pmol/L	42 vs. 14 34 vs. 22	3.64 (0.24–56.3)	0.355
Tumor diameter	≤20 vs. >20 mm	33 vs. 23	1.098 (0.074–16.3)	0.946
Extrathyroidal extension	no vs. yes	46 vs. 10	2.21 (0.12–41.5)	0.595
Prognostic groups	N0/N1a-NPNL vs. N1b-NPNL3	44 vs. 12	17.9 (1.33–241.4)	0.030
Preoperative calcitonin level	≤500 vs. >500	34 vs. 22
Prognostic groups	pmol/L N0/N1a-NPNL vs. N1b-NPNL3	44 vs. 12	2.46 (0.095–63.7)	0.587
Tumor diameter	≤20 vs. >20 mm	33 vs. 23	48.9 (7.4–322.9)	<0.001
Extrathyroidal extension	no vs. yes	46 vs. 10	3.53 (0.11–111.5)	0.474
Biochemical cure2	yes vs. no	42 vs. 14	4.15 (0.32–53.8)	0.277
Prognostic groups	N0/N1a-NPNL vs. N1b-NPNL3	44 vs. 12
Preoperative calcitonin level	<500 vs. >500 pmol/L	34 vs. 22	3.37 (0.019–606.5)	0.647
Tumor diameter	≤20 vs. >20 mm	33 vs. 23	1.37 (0.007–252.8)	0.907
Extrathyroidal extension	no vs. yes	46 vs. 10	97.2 (3.49–2,705.3)	0.007
Biochemical cure2	yes vs. no	42 vs. 14	18.7 (1.38–252.4)	0.028

Logistic regression, in 3 analysis, with biochemical cure, preoperative levels of calcitonin, and prognostic groups as dependent variables. CI, confidence interval; NPNL, no clinical progression to next tumor level.

¹Patients with Mx or M1 at primary surgery or progression to next clinical tumor level were excluded.

²After completed primary surgery.

³Ipsi- and contralateral pN1b in 1 patient and ipsilateral pN1b in 11 patients.